Charles Schwab’s Rhythm Pharmaceuticals RYTM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $61.4M | Buy |
552,738
+26,279
| +5% | +$2.38M | 0.01% | 1101 |
|
|
2026
Q1 | $45.8M | Sell |
526,459
-5,988
| -1% | -$582K | 0.01% | 1225 |
|
|
2025
Q4 | $57M | Buy |
532,447
+4,525
| +0.9% | +$480K | 0.01% | 1062 |
|
|
2025
Q3 | $53.3M | Buy |
527,922
+66,484
| +14% | +$6.17M | 0.01% | 1125 |
|
|
2025
Q2 | $29.2M | Buy |
461,438
+16,009
| +4% | +$980K | 0.01% | 1441 |
|
|
2025
Q1 | $23.6M | Buy |
445,429
+5,179
| +1% | +$287K | ﹤0.01% | 1547 |
|
|
2024
Q4 | $24.6M | Buy |
440,250
+6,384
| +1% | +$353K | ﹤0.01% | 1584 |
|
|
2024
Q3 | $22.7M | Buy |
433,866
+5,908
| +1% | +$283K | ﹤0.01% | 1629 |
|
|
2024
Q2 | $17.6M | Buy |
427,958
+21,213
| +5% | +$847K | ﹤0.01% | 1755 |
|
|
2024
Q1 | $17.6M | Buy |
406,745
+9,060
| +2% | +$397K | ﹤0.01% | 1691 |
|
|
2023
Q4 | $18.3M | Buy |
397,685
+12,937
| +3% | +$408K | ﹤0.01% | 1647 |
|
|
2023
Q3 | $8.82M | Buy |
384,748
+34,189
| +10% | +$766K | ﹤0.01% | 1981 |
|
|
2023
Q2 | $5.78M | Buy |
350,559
+122,522
| +54% | +$2.21M | ﹤0.01% | 2182 |
|
|
2023
Q1 | $4.07M | Sell |
228,037
-1,879
| -0.8% | -$47.2K | ﹤0.01% | 2296 |
|
|
2022
Q4 | $6.7M | Buy |
229,916
+25,647
| +13% | +$659K | ﹤0.01% | 2057 |
|
|
2022
Q3 | $5M | Buy |
204,269
+31,539
| +18% | +$587K | ﹤0.01% | 2215 |
|
|
2022
Q2 | $717K | Sell |
172,730
-125,595
| -42% | -$687K | ﹤0.01% | 2922 |
|
|
2022
Q1 | $3.44M | Buy |
298,325
+9,219
| +3% | +$80.9K | ﹤0.01% | 2457 |
|
|
2021
Q4 | $2.89M | Buy |
289,106
+22,744
| +9% | +$255K | ﹤0.01% | 2576 |
|
|
2021
Q3 | $3.48M | Sell |
266,362
-1,269
| -0.5% | -$19.4K | ﹤0.01% | 2541 |
|
|
2021
Q2 | $5.24M | Buy |
267,631
+15,409
| +6% | +$320K | ﹤0.01% | 2327 |
|
|
2021
Q1 | $5.37M | Buy |
252,222
+43,349
| +21% | +$1.26M | ﹤0.01% | 2267 |
|
|
2020
Q4 | $6.21M | Buy |
208,873
+3,132
| +2% | +$79.6K | ﹤0.01% | 2114 |
|
|
2020
Q3 | $4.46M | Sell |
205,741
-4,383
| -2% | -$100K | ﹤0.01% | 2116 |
|
|
2020
Q2 | $4.69M | Buy |
210,124
+22,703
| +12% | +$443K | ﹤0.01% | 2062 |
|
|
2020
Q1 | $2.85M | Buy |
187,421
+3,909
| +2% | +$70K | ﹤0.01% | 2113 |
|
|
2019
Q4 | $4.21M | Buy |
183,512
+52,296
| +40% | +$1.16M | ﹤0.01% | 2106 |
|
|
2019
Q3 | $2.83M | Buy |
131,216
+2,877
| +2% | +$61.7K | ﹤0.01% | 2252 |
|
|
2019
Q2 | $2.82M | Buy |
128,339
+18,917
| +17% | +$478K | ﹤0.01% | 2239 |
|
|
2019
Q1 | $3M | Buy |
109,422
+4,900
| +5% | +$141K | ﹤0.01% | 2218 |
|
|
2018
Q4 | $2.81M | Sell |
104,522
-1,271
| -1% | -$35.1K | ﹤0.01% | 2192 |
|
|
2018
Q3 | $3.09M | Buy |
105,793
+58,198
| +122% | +$1.84M | ﹤0.01% | 2269 |
|
|
2018
Q2 | $1.49M | Buy |
47,595
+15,695
| +49% | +$429K | ﹤0.01% | 2464 |
|
|
2018
Q1 | $635K | Buy |
31,900
+819
| +3% | +$21.7K | ﹤0.01% | 2663 |
|
|
2017
Q4 | $904K | Buy |
+31,081
| New | +$822K | ﹤0.01% | 2539 |
|
Other funds holding RYTM
RCM
BBA
PA
Charles Schwab's RYTM Position: Q2 2026 in Review
Charles Schwab increased its Rhythm Pharmaceuticals (RYTM) stake by 5% in Q2 2026, buying an estimated $2.38M and bringing the position to 552,738 shares worth $61.4M. The position accounts for 0.01% of the portfolio, ranked #1101.
Charles Schwab first reported a position in RYTM in Q4 2017 and has held it in 35 quarters since. 302 funds tracked by Wall St. Rank hold RYTM as of Q2 2026.
- Charles Schwab held 552,738 shares of Rhythm Pharmaceuticals worth $61.4M as of Q2 2026.
- Charles Schwab bought 26,279 Rhythm Pharmaceuticals shares in Q2 2026, an estimated $2.38M.
- Rhythm Pharmaceuticals made up 0.01% of Charles Schwab's portfolio in Q2 2026, its #1101 holding.
- Charles Schwab first reported a position in Rhythm Pharmaceuticals in Q4 2017 and has held it in 35 quarters since.
- 302 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q2 2026.
Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.